Monograph Details
|
|
Central Nervous System
> Seizure disorders
|
|
GABITRIL |
| Manufacturer |
|
Cephalon, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
GABA reuptake inhibitor. |
| Generic Name |
|
Tiagabine HCl 2mg, 4mg, 12mg, 16mg; tabs. |
| Indications |
|
Adjunct in partial seizures. |
| Children |
|
Not recommended. |
| Adults |
|
Take with food. Use lower doses and titrate slower if not on concomitant enzyme-inducing drug(s). 12–18yrs: 4mg once daily for 1 week; may increase to 8mg/day in 2 divided doses for 1 week; then may increase by 4–8mg weekly to clinical response or up to 32mg/day in 2–4 divided doses. ≥18yrs: 4mg once daily for 1 week; may increase by 4–8mg weekly to clinical response or up to 56mg/day in 2–4 divided doses. |
| Precautions |
|
Hepatic impairment: reduce dose. Reduce dose or discontinue if generalized weakness occurs. Adjust dose if spike and wave discharges on EEG with cognitive or neuropsychiatric events occur. Suicidal tendencies (monitor). Avoid abrupt cessation. Elderly. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
CNS depression potentiated by alcohol, triazolam, other CNS depressants. Tiagabine levels reduced by enzyme inducers (eg, phenytoin, carbamazepine, primidone, phenobarbital). May interact with valproate (monitor). May affect or be affected by highly protein bound drugs. |
| Adverse Reactions |
|
Dizziness, asthenia, somnolence, fatigue, GI upset/pain, nervousness, tremor, abdominal pain, concentration difficulties, dysphasia, confusion, other CNS effects, serious rash; possible long-term ophthalmologic effects. |
| How Supplied |
|
Tabs—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
